# Single and Repeat Doses of DMT in Healthy Subjects

> **NCT05559931** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Algernon Pharmaceuticals** · enrollment: 60 (estimated)

## Conditions studied

- Stroke

## Interventions

- **DRUG:** N,N-Dimethyltryptamine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05559931
- **Lead sponsor:** Algernon Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-01-13
- **Primary completion:** 2026-03
- **Final completion:** 2026-03
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-01-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05559931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05559931, "Single and Repeat Doses of DMT in Healthy Subjects". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT05559931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*